Pharmaceutical company
Appears in 11 stories
Markets ranibizumab (Lucentis), the active control in BRUNELLO
Merck said Thursday its experimental eye drug remigromig hit the primary endpoint in a 984-patient trial for diabetic macular edema. Both tested doses matched ranibizumab, the long-standing standard, on visual acuity at 52 weeks.
Updated 2 days ago
Sponsor of the IMAgINATION study and sefaxersen licensee
Roche's experimental IgA nephropathy drug sefaxersen met its phase 3 primary endpoint on September 23, cutting proteinuria versus placebo at 37 weeks in the IMAgINATION study. The result, from a prespecified interim look, was strong enough that Roche is taking it to health authorities and planning a medical meeting presentation.
Updated 3 days ago
Running phase 3 obesity trials, planning phase 3 diabetes trials
Roche's experimental once-weekly diabetes injectable cut blood sugar and body weight in a 48-week phase 2 trial announced September 22. Patients on the highest 24 mg dose saw HbA1c drop 2.65 percentage points and weight fall 15.5%.
Updated 4 days ago
Holds ex-China rights to Tam-Peli
Two rival antibody-drug conjugates just beat the standard of care in relapsed small-cell lung cancer. Roche-partnered Tam-Peli held median survival at 13.3 months; GSK's competitor got 18.5. Both faced the same decades-old chemotherapy — and that five-month gap is the story.
Updated Sep 14
Supplies atezolizumab (Tecentriq) for the zanzalintinib combination
Exelixis learned on September 10 that the FDA would delay its decision on zanzalintinib, its experimental colorectal cancer drug, by three months. The new deadline is March 3, 2027, after the agency deemed updated safety and efficacy data a major amendment to the application.
Updated Sep 11
Incumbent competitor via Hemlibra
People with hemophilia A can bleed for hours from a small cut and bleed inside their joints for no clear reason. Novo Nordisk says its experimental injection, denecimig, kept most patients bleed-free in a long-term trial: about 71% of adults and teens and about 89% of children had zero treated bleeds.
Updated Aug 11
Acquirer
For a century, the cancer diagnosis that decides a patient's treatment has come from a pathologist staring at a tumor slide through a microscope. Software is now doing that reading—and the pharmaceutical companies that sell the drugs are buying the companies that built the software. On May 7, Roche agreed to pay up to $1.05 billion for PathAI, the largest independent AI pathology firm in the United States.
Updated May 31
Advancing competing BBB-crossing platform for Alzheimer's disease
For decades, the blood-brain barrier has blocked nearly all large-molecule drugs from reaching the brain — a biological wall that left most neurological diseases effectively untreatable with modern biologics. On March 25, 2026, the FDA approved Denali Therapeutics' AVLAYAH. It's the first drug specifically engineered to cross the blood-brain barrier and deliver a therapeutic enzyme to the central nervous system after a simple intravenous infusion.
Updated May 30
Running parallel Phase 3 trial of zosurabalpin for CRAB
No genuinely new class of antibiotic has reached patients since 1987, and in the nearly four decades since, bacteria have steadily evolved resistance to existing drugs. Carbapenem-resistant Acinetobacter baumannii—a hospital-acquired pathogen that kills up to 60 percent of ventilated pneumonia patients—is at the top of the WHO's list of critical-priority threats. On March 16, 2026, Swiss biotech BioVersys received FDA clearance to enroll American patients in a Phase 3 pivotal trial of BV100, which reduced 28-day mortality by half in earlier testing.
Incumbent; markets Xolair (with Novartis) for food allergy
For decades, the 27 million American adults and children with food allergies had one option: avoid the allergen and carry an EpiPen. That changed in February 2024 when the FDA approved Xolair as the first drug to reduce allergic reactions—including anaphylaxis—from accidental exposure to multiple foods.
Updated May 22
Leading the BTK inhibitor race, awaiting final trial data
The FDA rejected Sanofi's tolebrutinib for progressive MS on December 28, 2025—a crushing blow for a drug that had won Breakthrough Therapy status and became the first BTK inhibitor approved anywhere in the world. Meanwhile, Roche's rival drug fenebrutinib is racing toward approval after strong Phase 3 results, and Merck's evobrutinib crashed out entirely. Three pharma giants bet billions that brain-penetrating BTK inhibitors could finally slow the relentless neurodegeneration that leaves MS patients in wheelchairs, and only one looks likely to reach the finish line first.
Updated May 16
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
